Home Physical Sciences The crystal structure of 1-propyl-2-nitro-imidazole oxide, C6H9N3O3
Article Open Access

The crystal structure of 1-propyl-2-nitro-imidazole oxide, C6H9N3O3

  • Yuan Jun ORCID logo EMAIL logo , Wu Bingheng , Wang Yong ORCID logo , Wang Jianlong , Cao Duanlin and Chen Lizhen
Published/Copyright: July 20, 2023

Abstract

C6H9N3O3, monoclinic, P21/n (no. 14), a = 9.5584(4) Å, b = 6.7828(3) Å, c = 12.8337(6) Å, β = 103.8810(10), V = 807.74(6) Å3, Z = 4, R gt (F) = 0.0455, wR ref (F2) = 0.1166, T = 170.0 K.

CCDC no.: 2279120

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Yellow block
Size: 0.19 × 0.11 × 0.08 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.11 mm−1
Diffractometer, scan mode: Bruker D8 VENTURE, φ and ω
θmax, completeness: 26.4°, >99 %
N(hkl)measured, N(hkl)unique, Rint: 8219, 1656, 0.070
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 1249
N(param)refined: 110
Programs: Bruker [1], Olex2 [2], SHELX [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
C1 0.82371 (17) 0.4440 (3) 0.39770 (13) 0.0241 (4)
C2 0.90309 (19) 0.1523 (3) 0.36484 (14) 0.0287 (4)
H2 0.943279 0.023568 0.374012 0.034*
C3 0.85424 (19) 0.2483 (3) 0.26969 (14) 0.0296 (4)
H3 0.854303 0.197023 0.200815 0.036*
C4 0.73662 (19) 0.5687 (3) 0.20419 (14) 0.0308 (4)
H4A 0.768380 0.538465 0.137975 0.037*
H4B 0.767983 0.704504 0.226611 0.037*
C5 0.57344 (19) 0.5573 (3) 0.18062 (15) 0.0361 (5)
H5A 0.541503 0.586579 0.246867 0.043*
H5B 0.541799 0.421872 0.157444 0.043*
C6 0.5040 (2) 0.7028 (4) 0.09325 (16) 0.0445 (6)
H6A 0.542473 0.681950 0.029894 0.067*
H6B 0.525237 0.837705 0.119647 0.067*
H6C 0.399397 0.682458 0.073954 0.067*
N1 0.88375 (15) 0.2749 (2) 0.44444 (11) 0.0247 (4)
N2 0.80546 (15) 0.4292 (2) 0.28956 (11) 0.0256 (4)
N3 0.78556 (16) 0.6056 (2) 0.45405 (12) 0.0299 (4)
O1 0.92014 (14) 0.2340 (2) 0.54645 (9) 0.0351 (4)
O2 0.81129 (15) 0.5961 (2) 0.55222 (10) 0.0433 (4)
O3 0.72789 (15) 0.7484 (2) 0.40112 (11) 0.0425 (4)

1 Source of material

All of reagents were purchased with analysis grade. In representative experiments, 7.05 g hydroxylamine hydrochloride (NH2OH⋅HCl), 5.3 g sodium carbonate (Na2CO3), 14.5 g glyoxal (C2H2O2), 9.7 g formaldehyde (CH2O), 8.9 g L-alanine (C3H7NO2) were added in the ice bath, and reacted at 273 K for 12 h. Then added 6.3 g nitric acid (HNO3) and the target compound were obtained by reaction at 273 K for 12 h. The crystal of the title compound was obtained by slow evaporation at 293 K.

2 Experimental details

Using Olex2 [2], the structure was solved with the ShelXT [3] structure solution program and refined with the ShelXL [3] refinement package. All H atoms were positioned geometrically and treated as riding, and Uiso(H) = 1.2 Ueq(C).

3 Comment

Nitroimidazoles have had attention for a variety of applications and are used in pharmaceutical industry and medical fields, such as 5-nitroimidazole and 2-nitroimidazole [5], [6], [7], [8], [9]. Nitroimidazole–N-oxides are compounds that have a nitro group and an oxide connected to the heterocyclic ring at the same time, thus such compounds are amazing and expect to have special value. And the title compound 1-propyl-2-nitro-imidazole oxide is expected to have important research value.

The title compound has been reported for the first time in this paper (cf. the figure). The imidazole ring is flat, and the angle between propyl and imidazole-oxides, is about 175.8°. The geometric parameters are in the expected ranges [10].


Corresponding author: Yuan Jun, Shanxi College of Technology, Shanxi College of Technology, Shuozhou, 036000, Shanxi Provience, P.R. China, E-mail:

Funding source: Shanxi Province Higher Education Science and Technology Innovation

Award Identifier / Grant number: 2022L619

Acknowledgements

We thank the Center of Testing and Analysis, Shanghai Institute, for support.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: 2022 Shanxi Province Higher Education Science and Technology Innovation Project 2022L619.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. BRUKER. SAINT, APEX2 and SADABS; Bruker AXS Inc: Madison, Wisconsin, USA, 2009.Search in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. Olex2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar PubMed PubMed Central

4. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar PubMed

5. Gisbert, J. P., González, L., Calvet, X., García, N., López, T., Roqué, M., Gabriel, R., Pajares, J. M. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 2000, 14, 1319–1328; https://doi.org/10.1046/j.1365-2036.2000.00844.x.Search in Google Scholar PubMed

6. Nunn, A., Linder, K., Strauss, H. W. Nitroimidazoles and imaging hypoxia. Eur. J. Nucl. Med. 1995, 22, 265–280; https://doi.org/10.1007/bf01081524.Search in Google Scholar PubMed

7. Torreele, E., Trunz, B. B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A., Pécoul, B. Fexinidazole-A new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 2010, 4, e923; https://doi.org/10.1371/journal.pntd.0000923.Search in Google Scholar PubMed PubMed Central

8. Upcroft, J. A., Dunn, L. A., Wright, J. M., Benakli, K., Upcroft, P., Vanelle, P. 5–Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis. Antimicrob. Agents Chemother. 2006, 50, 344–347; https://doi.org/10.1128/aac.50.1.344-347.2006.Search in Google Scholar

9. Lord, E. M., Harwell, L., Koch, C. J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993, 53, 5721–5726.Search in Google Scholar

10. Yuan, J., Wu, B., Wang, Y., Wang, J., Cao, D., Chen, L. The crystal structure of 1-ethyl-2-nitro-imidazole oxide, C5H7N3O3. Z. Kristallogr N. Cryst. Struct. 2023, 238, 743–744; https://doi.org/10.1515/ncrs-2023-0182.Search in Google Scholar

Received: 2023-06-08
Accepted: 2023-07-04
Published Online: 2023-07-20
Published in Print: 2023-10-26

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of (N-([1,1′:4′,1″-terphenyl]-4,4′-diethyl)-2-(bis(pyridin-2-ylmethyl)amino)acetamide-κ4N,N,N″, O)tri(nitrato-kO, O′) samarium(III) - methanol - acetonitrile (1/1/1), C40H39SmN8O14
  4. The crystal structure of 6,6′-(((2-(dimethylamino)ethyl)azanediyl)bis(methylene))bis(2-chloro-4-methyl phenolate-κ4N,N,O,O′)-(pyridine-2,6-dicarboxylato-N,O,O′)-titanium(IV), C27H27Cl2N3O6Ti
  5. N′-[(1E)-(4–Fluorophenyl)methylidene]adamantane-1-carbohydrazide, C18H21FN2O
  6. Crystal structure of 4-bromo-3-nitro-1H-pyrazole-5-carboxylic acid monohydrate, C4H2N3BrO4·H2O
  7. Crystal structure of dipyridine-k1N-tris(2,2,6,6-tetramethyl-5-oxohept-3-en-3-olato-k2O,O′)dysprosium(III), DyC43H67O6N2
  8. Crystal structure of cyclo[tetraiodido-bis{μ2-1-[(benzotriazol-1-yl)methyl]-1-H-1,3-(2-isopropyl-imidazol)-k2N:N}dicadmiun(II)], C26H30N10Cd2I4
  9. The crystal structure of tert-butyl (E)-3-(2-(benzylideneamino)phenyl)-1H-indole-1-carboxylate, C26H24N2O2
  10. The crystal structure of 4-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4- dihydroquinolin-7-yl)-2-methylpiperazin-1-ium 2,5-dihydroxybenzoate methanol solvate, C27H32FN3O9
  11. Crystal structure of (μ2-1-(4,4′-bipyridine-κ2N:N′)-bis[diaqua-(4-iodopyridine-2,6-dicarboxylato-κ3O,N,O′)–cobalt(II)], C24H20Co2I2N4O12
  12. The crystal structure of dimethyl 4,4′-(10,20-diphenylporphyrin-5,15-diyl)dibenzoate dichloromethane solvate, C49H36N4O4Cl2
  13. (E)-2-((E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-ylidene)hydrazine-1-carbothioamide C14H23N3S1
  14. The crystal structure of [1-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinolin-2(1H)-one], C16H12F3NO
  15. Crystal structure of (E)-2-amino-N′-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)methylene)benzohydrazide – dimethylformamide – water (1/1/2), C15H16N4O3·C3H7NO·2H2O
  16. Crystal structure of 3-(4-bromophenyl)-5-methyl-1H-pyrazole, C10H9BrN2
  17. Crystal structure of 1,10-phenanthrolinium bromide dihydrate, C12H9N2Br
  18. Crystal structure of N-(4′-chloro-[1,1′-biphenyl]-2-yl)formamide, C13H10ClNO
  19. The crystal structure of nitroterephthalic acid, C8H5NO6
  20. Crystal structure of (2-((4-bromo-2,6-dichlorophenyl)amino)phenyl) (morpholino)methanone, C17H15BrCl2N2O2
  21. Crystal structure of tetraaqua-bis(ethanol-κO)-tetrakis(μ2-trifluoroacetate-κ2O:O′)-bis(trifluoroacetate-κ2O)digadolinium(III) Gd2C16H20O18F18
  22. The crystal structure of dimethyl 4,4′-[10,20-bis(2,6-difluorophenyl)porphyrin-5,15-diyl]dibenzoate chloroform solvate, C50H32Cl6F4N4O4
  23. The crystal structure of N,N′-((nitroazanediyl)bis(methylene))diacetamide, C6H12O4N4
  24. The crystal structure of [bis(2,2′-bipyridine-6-carboxylato-κ3N,N,O)magnesium(II)]dihydrate, C22H18N4O6Mg
  25. Crystal structure of poly[diaqua-(bis(μ2-1,4-bis(imidazol-1-ylmethyl)benzene)-κ2N,N′] cobalt(II)-tetraqua-bis(1,4-bis(imidazol-1-ylmethyl)benzene)-κ1N)-cobalt(II) di(2,5-thiophenedicarboxylate) dihydrate, C68H76Co2N16O16S2
  26. Crystal structure of poly[chlorido-μ2-chlorido-(μ2-1-[(2-ethyl-4-methyl-1H-imidazol-1-yl)methyl]-1H-benzotriazole-κN:N’)cadmium(II)], C13H15CdN5Cl2
  27. The crystal structure of (4-hydroxybenzenesulfonate)-k1O-6,6′-((1E,1′E)- (ethane-1,2-diylbis(azaneylylidene))bis(methaneylylidene)) bis(2-methoxyphenol)-κ2N,N,μ2O,O2O, O)-(methanol)-cobalt(II) sodium(I), C25H27CoN2NaO9S
  28. Crystal structure of (1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)(4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)amino)piperidin-1-yl)methanone, C17H18F6N6O
  29. Crystal structure of bis{[(cyclohexylimino)(phenylimino)-l5-(methyl)diethylazane-κ2N:N′]-(ethyl)-zinc(II)]}, C38H62N6Zn2
  30. Crystal structure of 2-[(4-bromobenzyl)thio]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C13H8Br2N2OS2
  31. Crystal structure of 10-methoxy-7,11b,12,13-tetrahydro-6H-pyrazino [2′,3′:5,6]pyrazino[2,1-a]isoquinoline, C15H16N4O
  32. The crystal structure of 1-propyl-2-nitro-imidazole oxide, C6H9N3O3
  33. The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid–2-ethoxybenzamide (1/1), C17H16N2O8
  34. The structure of RUB-1, (C8H16N)6[B6Si48O108], a boron containing levyne-type zeolite, occluding N-methyl-quinuclidinium in the cage-like pores
  35. The crystal structure of diaqua-(naphthalene-4,5-dicarboxylate-1,8-dicarboxylic anhydride1O)-(4′-(4-(1H-benzimidazolyl-1-yl)phenyl)-2,2′:6′,2″-terpyridine-κ3N,N′,N″)–manganese(II) dihydrate, C42H27MnN5O9·2H2O
  36. Crystal structure of 6,6′-((1E,1′E)-hydrazine-1,2-diylidenebis(methanylylidene))bis (3-(3-bromopropoxy)phenol), C20H22Br2N2O4
  37. The crystal structure of 3-(2-hydroxyphenyl)-4-phenyl-6-(p-tolyl)-2H-pyran-2-one, C24H18O3
  38. Crystal structure of bis(μ2-2-(1,5-dimethyl–3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)imino)methyl)phenolato-κ4O:O,N,O′)-(nitrato-κ2O,O′)dicobalt(II), C36H32Co2N8O4
  39. Synthesis and crystal structure of (3E,5S,10S,13S,14S,17Z)-17-ethylidene-10,13-dimethylhexadecahydro-3H-cyclopenta[α] phenanthren-3-one O-(4-fluorobenzoyl) oxime, C28H36FNO2
  40. The crystal structure of 4-aminiumbiphenyl benzenesulfonate, C18H17NO3S
  41. Synthesis and crystal structure of 1-(7-hydroxy-3-(4-hydroxy-3-nitrophenyl)-4-oxo-4H-chromen-8-yl)-N,N-dimethylmethanaminiumnitrate, C18H17N3O9
  42. Crystal structure of N-(Ar)-N′-(Ar′)-formamidine, C14H12Br2N2O
  43. The crystal structure of 4-(2,4-dichlorophenyl)-2-(4-fluorophenyl)-5-methyl-1H-imidazole, C16H11Cl2FN2
  44. Crystal structure of 1-(4–chlorophenyl)-4-benzoyl-3-methyl-1H-pyrazol-5-ol, C17H13ClN2O2
  45. The crystal structure of 5-amino-1-methyl-4-nitroimidazole, C4H6O2N4
  46. Crystal structure of 1,3-diisopropyl-4,5-dimethylimidazol-2-ylidene-N,N′-bis(1,3-bis(2,6-diisopropylphenyl)-1,3-dihydro-2H-1,3,2-diazaborol-2-yl)-l2-germenediamine, C63H94B2GeN8
  47. The crystal structure of (bromido, chlorido)-tricarbonyl-(5,5′-dimethyl-2,2′-bipyridine)-rhenium(I), C15H12Br0.2Cl0.8N2O3Re1
  48. Crystal structure of [N(E),N′(E)]-N,N′-(1,4-phenylenedimethylidyne)bis-3,5-bis(propan-2-yl)-1H-pyrazol-4-amine, C26H36N6
  49. The crystal structure of poly[2-(4-carboxypyridin-3-yl)terephthalpoly[diaqua-(μ4-2-(6-carboxylatopyridin-3-yl)terephthalato-κ5O,N:O′:O″,O‴)]) cadmium(II)] dihydrate, C28H20Cd3N2O16
  50. Crystal structure of [tetraaqua-bis((3-carboxy-5-(pyridin-4-yl)benzoate-κ1N)cobalt(II)] tetrahydrate, C26H32CoN2O16
  51. Crystal structure of bis(μ2-azido-κ2N:N)-tetrakis(azido-κ1N)-tetrakis(1,10-phenanthroline-κ2N,N′)dibismuth(III), C48H32N26Bi2
  52. Crystal structure of (Z)-N-(4-(4-(4-((4,5,6-trimethoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)butoxy)phenyl)acetamide, C30H31NO8
  53. Crystal structure of poly[diaqua-(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2N:N′)-bis(μ2-5-carboxybenzene-1,3-dicarboxylato-O,O′:O″)-aqua-di-zinc dihydrate solvate], C27H28N4O16Zn2
  54. Crystal structure of 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)malononitrile, C12H14N2
  55. Crystal structure of chlorido-(5-nitro-2-phenylpyridine-κ2N,C)-[(methylsulfinyl)methane-κ1S]platinum(II), C13H13ClN2O3PtS
  56. The crystal structure of the co-crystal 1,4-dioxane–4,6-bis(nitroimino)-1,3,5-triazinan-2-one(2/1), C11H19N7O9
  57. Crystal structure of [N(E),N′(E)]-N,N′-(1,4-phenylenedimethylidyne)bis-3,5-dimethyl-1H-pyrazol-4-amine di-methanol solvate, C18H20N6·2(CH3OH)
  58. Crystal structure of catena-poly[bis(μ2-azido-k2N:N′)-(nitrato-K2N:N′)-bis(1,10-phenanthroline-K2N:N′)samarium(III)], C24H16N11O3Sm
  59. Crystal structure of (Z)-2-(4-((5-bromopentyl)oxy)benzylidene)-4,5,6-trimethoxybenzofuran-3(2H)-one, C23H25BrO6
  60. Crystal structure of bis(3,5-dimethyl-1H-pyrazol-4-ammonium) tetrafluoroterephthate, 2[C5H10N3][C8F4O4]
  61. Crystal structure of 2-amino-4-(2-fluoro-4-(trifluoromethyl)phenyl)-9-methoxy-1,4,5,6-tetrahydrobenzo[h]quinazolin-3-ium chloride, C20H18ClF4N3O
  62. Crystal structure of 6-(pyridin-3-yl)-1,3,5-triazine-2,4-diamine-sebacic acid (2/1), C13H17N6O2
Downloaded on 20.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2023-0274/html
Scroll to top button